{'fraction_non_alphanumeric': 0.0484304932735426, 'fraction_numerical': 0.009865470852017937, 'mean_word_length': 5.340909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Options Emerge for Relapsed/Refractory Hodgkin Lymphoma

NEW YORK—Multiple options are emerging for the treatment of third-line Hodgkin lymphoma (HL), including repurposed drugs, HL-specific drugs, and chimeric antigen receptor (CAR) T-cell therapy. “In pre-modern times, there were no conventional curative options for HL and patients historically had a poor prognosis. With allogeneic transplantation, the usual progression-free survival (PFS) rose to 25-30 percent. Modern series of transplantation has improved 2to 3-year PFS to more than 50 percent,” said Philippe Armand, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, speaking at the National Comprehensive Cancer Network Annual Congress on Hematologic Malignancies. “In modern times, we have repurposed anti-lymphoma agents and HL-specific agents. CAR T cells are truly emerging agents.” A handful of repurposed drugs now show promise in relapsed/refractory HL, with the duration of PFS extended to 9 months. These agents include a combination of gemcitabine, navelbine, and doxorubicin liposomal (9-month PFS); bendamustine (about 6-month PFS);